Silence Therapeutics plc entered into an underwriting agreement on August 11, 2026, to sell 12,962,963 American Depositary Shares (ADSs) in an underwritten public offering. Each ADS represents three ordinary shares and was priced at $13.50 per share. The company granted the underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs. Net proceeds are estimated at approximately $164.0 million, or $188.7 million if the over-allotment option is exercised in full, after deducting underwriting discounts and offering expenses. The closing of the offering is expected to occur on August 13, 2026. Jefferies LLC and Morgan Stanley & Co. LLC are acting as representatives for the underwriters. Silence Therapeutics plc operates in the biotechnology industry, developing short interfering RNA (siRNA) therapies.

Silence Therapeutics plc announced positive topline results from the Phase 2 SANRECO trial of divesiran for polycythemia vera (PV). The trial met its primary endpoint, with an 88% clinical response rate for divesiran versus 19% for placebo. Both dosing regimens showed efficacy: 93.8% for every six weeks and 81.3% for every twelve weeks. Secondary endpoints were also met, including a significant reduction in phlebotomy rates (0.2 vs 2.1 per patient). The drug was well-tolerated with no new safety findings. Based on these results, the company plans to initiate a Phase 3 trial evaluating divesiran for Q12W dosing versus placebo in the first half of 2027. Silence Therapeutics plc is a global clinical-stage biotechnology company developing novel siRNA therapies.

Silence Therapeutics plc reported financial results for the second quarter ended June 30, 2026. The company posted a net loss of $12.3 million, or $0.09 per share, compared to a net loss of $27.4 million in the prior year period. Research and development expenses decreased to $9.1 million from $17.6 million, primarily due to completed Phase 3 readiness for zerlasiran and reduced personnel costs. Cash and cash equivalents stood at $72.1 million as of June 30, 2026. Business highlights include the completion of patient dosing in the Phase 2 SANRECO trial for divesiran in polycythemia vera and positive preclinical data for SLN365 and SLN098. Silence Therapeutics is a global clinical-stage biotechnology company developing siRNA therapies.

Silence Therapeutics plc entered into a separation and release agreement with former executive Craig Tooman, effective as of December 14, 2025. The agreement includes $655,000 in salary continuation, a $250,000 lump sum severance, $40,000 in legal fee reimbursement, a $283,746.03 bonus payment, $46,896.48 in healthcare premium reimbursement, and extended post-termination exercise periods for vested options. Silence Therapeutics plc is a biotechnology company focused on developing RNA interference (RNAi) technology for therapeutic use.